Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Raltitrexed (Tomudex).

E Van Cutsem1

  • 1Department of Internal Medicine, UZ Gasthuisberg, Leuven, Belgium.

Expert Opinion on Investigational Drugs
|July 5, 2005
PubMed
Summary
This summary is machine-generated.

Raltitrexed offers an effective alternative for advanced colorectal cancer treatment. It shows similar efficacy to 5-fluorouracil plus leucovorin but with improved tolerability and patient acceptance.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A randomised study of encorafenib, cetuximab, and FOLFIRI versus FOLFIRI with or without bevacizumab in BRAF V600E-mutant colorectal cancer: BREAKWATER Cohort 3.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgroup analysis of the pivotal NAPOLI 3 trial.

ESMO open·2026
Same author

Managing adverse events in patients with metastatic colorectal cancer receiving trifluridine/tipiracil in combination with bevacizumab.

ESMO gastrointestinal oncology·2026
Same author

Health-related quality of life and performance status with NALIRIFOX versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma: results from the NAPOLI 3 trial.

ESMO open·2025
Same author

Quality-adjusted survival in patients with metastatic colorectal cancer treated with fruquintinib plus best supportive care: results from FRESCO-2.

ESMO open·2025
Same author

Profile of Persons Recently Infected with HIV-1 in Belgium: New Insights to Tailor Prevention Efforts.

AIDS and behavior·2024
Same journal

Investigational new drug TAP-1502 beginning clinical study for seborrheic dermatitis.

Expert opinion on investigational drugs·2026
Same journal

Cannabinoid use in adults with sickle cell disease: therapeutic development and clinical insights.

Expert opinion on investigational drugs·2026
Same journal

Odronextamab: a bispecific antibody for follicular lymphoma.

Expert opinion on investigational drugs·2026
Same journal

Evaluating the investigational drug landscape for <i>ESR1</i>-mutated, estrogen receptor-positive, HER2-negative metastatic breast cancer.

Expert opinion on investigational drugs·2026
Same journal

Darigabat and subtype-selective GABA-A modulation: pharmacology, clinical development, and translational challenges.

Expert opinion on investigational drugs·2026
Same journal

Safety, tolerability, and pharmacokinetics of HL-300, a novel topical pan-JAK inhibitor, in healthy Chinese adults: a first-in-human, randomized, double-blind, placebo-controlled phase I trial.

Expert opinion on investigational drugs·2026
See all related articles

Area of Science:

  • Medical Oncology
  • Pharmacology

Background:

  • Colorectal cancer remains a significant global health challenge.
  • Current therapies, such as 5-fluorouracil plus leucovorin (5-FU + LV), have limitations in terms of toxicity and patient tolerance.

Purpose of the Study:

  • To evaluate the efficacy and safety of raltitrexed as a treatment for advanced colorectal cancer.
  • To compare raltitrexed monotherapy with combination 5-FU + LV regimens.

Main Methods:

  • Phase I, II, and III clinical studies were conducted.
  • Raltitrexed was administered intravenously at a maximum tolerated dose of 3.0 mg/m(2) every 3 weeks.
  • Efficacy and toxicity were compared between raltitrexed and 5-FU + LV regimens.

Main Results:

Related Experiment Videos

  • Raltitrexed demonstrated comparable efficacy to 5-FU + LV in advanced colorectal cancer.
  • Raltitrexed was associated with fewer severe toxicities, including leucopenia and mucositis.
  • Patients treated with raltitrexed experienced better tolerability and acceptance.

Conclusions:

  • Raltitrexed represents a viable and better-tolerated alternative to 5-FU-based chemotherapy for advanced colorectal cancer.
  • Its unique mechanism of action suggests potential for synergistic combinations with other therapeutic agents.